title: A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia.
abstract: Uric acid in serum (S-UA) is produced by the breakdown of the cellular nucleic acids of leukemia cells, and may be a marker of disease aggressiveness. S-UA levels were examined for association with clinical outcomes in patients with acute myeloid leukemia (AML). Fifty-six patients with AML admitted to our Institution were evaluated retrospectively. The median S-UA level at diagnosis was 5.0 mg/dl (range 2-13.8 mg/dl). The S-UA levels did not correlate with peripheral lactate dehydrogenase, peripheral white blood cell counts, or peripheral blast counts, and were not proportional to bone marrow blast counts or marrow cellularity. The S-UA levels in the patients who achieved complete remission were slightly lower than those in those who did not. S-UA levels less than, or equal to the median (5.0 mg/dl) were significantly associated with better prognoses, compared with S-UA levels greater than 5.0 mg/dl. Thus, the S-UA level may predict the prognosis of AML, and is a versatile and cost-effective test for such a purpose.
authors.affiliation: Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, 23 Shimoaizuki, Matsuoka, Eiheiji Fukui, 910-1193, Japan. tyamauch@u-fukui.ac.jp.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yamauchi
authors.forename: Eiju
authors.initials: E
authors.lastname: Negoro
authors.forename: Shin
authors.initials: S
authors.lastname: Lee
authors.forename: Mihoko
authors.initials: M
authors.lastname: Takai
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Matsuda
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Takagi
authors.forename: Shinji
authors.initials: S
authors.lastname: Kishi
authors.forename: Katsunori
authors.initials: K
authors.lastname: Tai
authors.forename: Naoko
authors.initials: N
authors.lastname: Hosono
authors.forename: Toshiki
authors.initials: T
authors.lastname: Tasaki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ikegaya
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Inai
authors.forename: Akira
authors.initials: A
authors.lastname: Yoshida
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Urasaki
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Iwasaki
authors.forename: Takanori
authors.initials: T
authors.lastname: Ueda
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D014527:Uric Acid / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D014527:Uric Acid; D007770:L-Lactate Dehydrogenase
keywords: AML; prognosis; uric acid